Insider Selling: Jazz Pharmaceuticals (NASDAQ:JAZZ) Director Sells $655,680.00 in Stock

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Director Norbert Riedel sold 3,415 shares of the stock in a transaction dated Friday, February 27th. The stock was sold at an average price of $192.00, for a total transaction of $655,680.00. Following the sale, the director directly owned 7,024 shares in the company, valued at approximately $1,348,608. The trade was a 32.71% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Jazz Pharmaceuticals Price Performance

Shares of Jazz Pharmaceuticals stock opened at $188.69 on Thursday. The firm has a market cap of $11.62 billion, a PE ratio of -31.61, a P/E/G ratio of 0.37 and a beta of 0.22. Jazz Pharmaceuticals PLC has a twelve month low of $95.49 and a twelve month high of $198.00. The company has a quick ratio of 1.67, a current ratio of 1.86 and a debt-to-equity ratio of 1.00. The business has a 50-day moving average price of $170.69 and a 200 day moving average price of $153.18.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its quarterly earnings results on Tuesday, February 24th. The specialty pharmaceutical company reported $6.64 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.49 by $0.15. The company had revenue of $1.20 billion for the quarter, compared to the consensus estimate of $1.17 billion. Jazz Pharmaceuticals had a positive return on equity of 6.87% and a negative net margin of 8.35%.Jazz Pharmaceuticals’s revenue for the quarter was up 8.1% on a year-over-year basis. During the same quarter in the prior year, the business posted $6.51 earnings per share. Sell-side analysts predict that Jazz Pharmaceuticals PLC will post 16.96 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Jazz Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Farther Finance Advisors LLC lifted its position in Jazz Pharmaceuticals by 754.8% during the third quarter. Farther Finance Advisors LLC now owns 265 shares of the specialty pharmaceutical company’s stock worth $35,000 after buying an additional 234 shares in the last quarter. Hilltop National Bank acquired a new stake in shares of Jazz Pharmaceuticals in the 4th quarter worth $36,000. Hantz Financial Services Inc. raised its holdings in shares of Jazz Pharmaceuticals by 471.4% during the 2nd quarter. Hantz Financial Services Inc. now owns 360 shares of the specialty pharmaceutical company’s stock worth $38,000 after acquiring an additional 297 shares during the period. LRI Investments LLC purchased a new position in shares of Jazz Pharmaceuticals during the 4th quarter worth $38,000. Finally, Danske Bank A S acquired a new position in shares of Jazz Pharmaceuticals during the 3rd quarter valued at about $40,000. Institutional investors and hedge funds own 89.14% of the company’s stock.

Analyst Ratings Changes

A number of research firms have weighed in on JAZZ. Piper Sandler restated an “overweight” rating and set a $219.00 price objective (up from $147.00) on shares of Jazz Pharmaceuticals in a research report on Wednesday, December 10th. UBS Group restated a “neutral” rating and set a $188.00 price target (up from $163.00) on shares of Jazz Pharmaceuticals in a research report on Monday, November 24th. Robert W. Baird raised their price target on shares of Jazz Pharmaceuticals from $160.00 to $209.00 and gave the company an “outperform” rating in a research note on Tuesday, November 18th. Needham & Company LLC boosted their price objective on Jazz Pharmaceuticals from $210.00 to $235.00 and gave the stock a “buy” rating in a research note on Monday, January 12th. Finally, Wall Street Zen raised Jazz Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Saturday, November 8th. Fourteen research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $214.57.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.